In particular, the BDNF Met gene carriers (aged 60 and older), which were in preclinical stages of AD, demonstrated reduced memory function and smaller hippocampal and temporal lobe volume as compared to Val homozygotes (Lim et al., 2013; Brown et al., 2014). This evidence concerns the gene BDNF and Alzheimer disease.